Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2021-03-23 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – French.pdf
Regulatory Filings
2021-03-23 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-03-23 English
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the issuance of units to settle interest owed to debenture holders. It details the terms of the units, including the composition of shares and warrants, and mentions the requirement for TSX Venture Exchange approval. The document does not contain financial statements or detailed financial analysis but rather communicates a financing-related transaction. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital structure and financing activities.
2021-03-05 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the issuance of units in settlement of interests owed to debenture holders. It details the number of units, the unit price, the composition of each unit (subordinate voting share and warrant), and conditions such as approval by the TSX Venture Exchange and a hold period. There are no financial statements, comprehensive financial data, or detailed financial analysis present. The document is not a full financial report, audit, or earnings release. It is an update on a financing activity related to the issuance of securities to settle debt interest. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4759 characters, which is sufficient to provide substantive information about the financing event rather than a mere announcement of a report publication or regulatory filing. Hence, the classification is CAP with high confidence.
2021-03-05 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Material Change Report' and references 'Schedule 51-102F3', which is a regulatory form used in Canadian securities regulation for reporting material changes. The content describes a significant clinical trial result announcement by Devonian Health Group Inc. It is a regulatory disclosure about a material event affecting the company, not a financial report, earnings release, or management discussion. The document length is 3541 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no financial data or detailed financial analysis present. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-01 English
Material change report - French.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'DÉCLARATION DE CHANGEMENT IMPORTANT' (Declaration of Material Change) and is filed under Annex 51-102A3, which corresponds to Canadian continuous disclosure requirements. It announces positive clinical trial results for a pharmaceutical product, Thykamine, and provides detailed information about the trial and its outcomes. The document is a formal announcement of a material change or event affecting the company, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the change itself. The document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure of a material event that does not fit other specific categories like earnings, management changes, or capital updates. The document length is 4092 characters, which is relatively short but contains detailed disclosure rather than just a notice of report availability.
2021-03-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.